This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-01. Anything still debated is marked as such rather than presented as settled.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Shelf life === The shelf life of canned evaporated milk varies according to both its added content and its proportion of fat. For the regular unsweetened product, a shelf life of 15 months may be expected before any noticeable destabilization occurs.
are neutrally buoyant or nearly so; in fact most cephalopods are about 2–3% denser than seawater), they achieve this in different ways. Some, such as Nautilus, allow gas to diffuse into the gap between the mantle and the shell; others allow purer water to ooze from their kidneys, forcing out denser salt water from the body cavity; others, like some fish, accumulate oils in the liver; and some octopuses have a gelatinous body with lighter chloride ions replacing sulfate in the body chemistry. Squids are the primary sufferers of negative buoyancy in cephalopods. The negative buoyancy means that some squids, especially those whose habitat depths are rather shallow, have to actively regulate their vertical positions. This means that they must expend energy, often through jetting or undulations, in order to maintain the same depth. As such, the cost of transport of many squids are quite high. That being said, squid and other cephalopod that dwell in deep waters tend to be more neutrally buoyant which removes the need to regulate depth and increases their locomotory efficiency. The Macrotritopus defilippi, or the sand-dwelling octopus, was seen mimicking both the coloration and the swimming movements of the sand-dwelling flounder Bothus lunatus to avoid predators. The octopuses were able to flatten their bodies and put their arms back to appear the same as the flounders as well as move with the same speed and movements. Females of two species, Ocythoe tuberculata and Haliphron atlanticus, have evolved a true swim bladder.
== Function == The TAP transporter is found in the ER lumen associated with the peptide-loading complex (PLC). This complex of β2 microglobulin, calreticulin, ERp57, TAP, tapasin, and MHC class I acts to keep hold of MHC molecules until they have been fully loaded with peptides.
== Physical properties == Ciprofol is an optically active 2,6-disubstituted alkylphenol with a cyclopropylethyl group incorporated at the second carbon atom. This cyclopropyl group increases the steric effects and introduces stereoselective effects over its anesthetic properties. These properties appear to increase the anesthetic potency of ciprofol, when compared with propofol.
Sources: en.wikipedia.org
glycogen A branched polysaccharide composed of as many as 30,000 covalently bonded units of the monosaccharide glucose which functions as the primary form of short-term energy storage in most animal cells. Glycogen reserves are especially abundant in muscle and liver cells, where they can be metabolized at-need into their component glucoses as a means of buffering blood sugar levels, a process known as glycogenolysis.
=== Wine laws and regulations === In the United States, the Alcohol and Tobacco Tax and Trade Bureau (TTB) limits the use of diammonium phosphate as a nitrogen additive to 968 mg/L (8 lbs/1000 gal) which provides 203 mg N/L of YAN. In the European Union, most countries follow the guidelines of the International Organisation of Vine and Wine (OIV) which dictates a limit of 300 mg/L. In Australia, the limit is based on the level of inorganic phosphate with a maximum limit of 400 mg/L of phosphate permitted.
If M1 and M2 are the midpoints of the diagonals AC and BD respectively in a tangential quadrilateral ABCD with incenter I, and if the pairs of opposite sides meet at J and K with M3 being the midpoint of JK, then the points M3, M1, I, and M2 are collinear. The line containing them is the Newton line of the quadrilateral. If the extensions of opposite sides in a tangential quadrilateral intersect at J and K, and the extensions of opposite sides in its contact quadrilateral intersect at L and M, then the four points J, L, K and M are collinear.
This reacts up to 400 fold faster than the original pair with a rate constant of 5.5 ± 0.6 × 105 M−1 s−1. This version is back reactive with the two previous generations of SpyTag/SpyCatcher reagents. SpyTag/SpyCatcher react with specificity even when in the presence of bacterial and mammalian cell environments.
== Indications/Symptoms == Typical symptoms after being bitten by a black mamba include the rapid onset of dizziness, drowsiness and coughing and having difficulties breathing. Other likely symptoms include convulsions, neuromuscular symptoms, shock, loss of consciousness, hypotension, ataxia, excessive salivation, limb paralysis, nausea and vomiting, fever, and severe abdominal pain. Permanent limb paralysis is very likely if the bite remains untreated. In the most severe case, if untreated, the bite of the black mamba can lead to death by suffocation, resulting from the paralysis of respiratory muscles. All these symptoms are due to a combination of all the toxic peptides the crude venom of the black mamba contains. The symptoms are related to calciseptine because it also works as a smooth muscle relaxant, thus explaining the early onset of having difficulties breathing, limb paralysis and even death by suffocation. Calciseptine is known to have a hypotensive effect. It cannot clearly be established which peptide is most responsible for which symptom, since combinations of different toxins can have various effects.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.